Pure Global

A Study of MHB039A for Advanced Solid Tumor - Trial NCT06345482

Access comprehensive clinical trial information for NCT06345482 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Minghui Pharmaceutical (Hangzhou) Ltd and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 196 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06345482
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06345482
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of MHB039A for Advanced Solid Tumor
A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety

Study Focus

Advanced Solid Tumor

MHB039A

Interventional

drug

Sponsor & Location

Minghui Pharmaceutical (Hangzhou) Ltd

Shanghai, China

Timeline & Enrollment

Phase 1/2

Apr 01, 2024

Jun 01, 2029

196 participants

Primary Outcome

Incidence of participants with adverse events (AE),Number of participants with dose-limiting toxicity (DLT)

Summary

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in
 advanced malignant tumors.

ICD-10 Classifications

Carcinoma in situ, unspecified
Malignant neoplasm: Prepuce
Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm of other connective and soft tissue

Data Source

ClinicalTrials.gov

NCT06345482

Non-Device Trial